Se connecter Inscription gratuite

Edesa Biotech Ret. sur les actifs

Quel est le Ret. sur les actifs de Edesa Biotech?

Le Ret. sur les actifs de Edesa Biotech, Inc. est -97.50%

Quelle est la définition de Ret. sur les actifs?



Le rendement des actifs indique dans quelle mesure les actifs d'une entreprise génèrent des revenus. Il est calculé en divisant le résultat net par l'actif total moyen.

The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.

Ret. sur les actifs des entreprises dans Health Care secteur sur NASDAQ par rapport à Edesa Biotech

Que fait Edesa Biotech?

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Entreprises avec ret. sur les actifs similaire à Edesa Biotech